Irritable bowel syndrome neuropharmacology: A review of approved and investigational compounds

Journal of Clinical Gastroenterology

Volumn 35, Issue 1 SUPPL., 2002, Pages

  Callahan, Michael J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 METHOXY 4 [5 (2 PIPERIDYLMETHYL) 1,2,4 OXADIAZOL 3 YL]ANILINE; ALOSETRON; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DARIFENACIN; DIZOCILPINE; DOPAMINE RECEPTOR BLOCKING AGENT; EZLOPITANT; FEDOTOZINE; HYOSCYAMINE; KAPPA OPIATE RECEPTOR ANTAGONIST; LOPERAMIDE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; NEPADUTANT; NOLPITANTIUM; PROKINETIC AGENT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SOLIFENACIN; TACHYKININ DERIVATIVE; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TS 951; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAMIFENACIN; CHOLECYSTOKININ RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; OPIATE RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; TACHYKININ RECEPTOR;

ABDOMINAL PAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; NEUROPHARMACOLOGY; PRIORITY JOURNAL; SIDE EFFECT; AUTONOMIC NERVOUS SYSTEM; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL THERAPY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC ANTAGONISTS; COLONIC DISEASES, FUNCTIONAL; HUMANS; PARASYMPATHOMIMETICS; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, TACHYKININ; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 0036089360     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200207001-00011     Document Type: Conference Paper

References (100)

1. Epidemiology of irritable bowel syndrome in the United States
2. Management of the irritable bowel syndrome
3. Functional gut disorders: From motility to sensitivity disorders. A review of current and investigational drugs for their management
4. Drug treatment options for irritable bowel syndrome: Managing for success
5. 4 agonist induces CAMP mediated Cl-flux from rat colonocytes
6. Use of the peripheral dopamine antagonists, domperidone, in the management of gastrointestinal symptoms in patients with the irritable bowel syndrome
7. Oral domperidone: Double-blind comparison with placebo in the irritable bowel syndrome
8. Domperidone treatment in the irritable bowel syndrome
9. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
10. Prokinetic treatment of constipation predominant irritable bowel syndrome: A placebo-controlled study of cisapride
11. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation
12. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized controlled trials
13. 4 receptor partial agonist relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
14. Validation of global relief measure in two clinical trials of irritable bowel syndrome with Tegaserod
15. Review article: Tegaserod
16. Serotonergic neuroenteric modulators
17. Therapy of irritable bowel syndrome: An overview
18. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects
19. The effect of oral cisapride on colonic transit
20. Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites
21. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
22. 4 receptors mediate the RO93877-induced changes in contractile patterns in the contractile patterns in the canine colon
23. Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers
24. 4 agonist, prucalopride in healthy humans
25. In vitro pharmacology of the novel enterokinetic RO93877
26. 4 receptor. I. Design of a new class of agonists and receptor map of the agonist recognition site
27. Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome
28. The effects of tegaserod (HTF919) on oesophageal acid exposure in gastroesophageal reflux disease
29. Tegaserod is well tolerated in diarrhea-predominant irritable bowel syndrome
30. 4 receptor agonist
31. 4 receptor agonist, TS-951, in vitro
32. Recombinant human neurotrophin-3 accelerates small bowel and colonic transit in healthy humans and patients with constipation
33. Tachykinins in the gut. Part I. Expression, release and motor function
34. Distribution of neurokinin A and neurokinin B-like immunoreactivity in human peripheral tissues
35. Distributions of neuropeptides in the human esophagus
36. Distribution and coexistence of peptides in nerve fibers of the external muscle of the human gastrointestinal tract
37. Tachykinins as transmitters of ascending contractile component of the peristaltic reflex
38. Human isolated ileum: Motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides
39. Substance P and substance K receptor binding sites in the human gastrointestinal tract: Localization by autoradiography
40. A double-blind parallel group pilot study of the effects of CJ-11974 and placebo on perceptual and emotional responses to rectosigmoid distention in IBS patients
41. Potent NKI antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation
42. Tachykinin-dependent and independent components of peristalsis in the guinea pig isolated distal colon
43. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist
44. Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder
45. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine
46. Chronic low-level administration of diquat increases the nociceptive response to gastric distension in rats: Role of mast cells and tachykinin receptor activation
47. Muscarinic receptors and gastrointestinal tract smooth muscle function
48. Controlled treatment trials in the irritable bowel syndrome: A critique
49. Treatment of irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)
50. Different therapeutic regimens in irritable bowel syndrome
51. Irritable colon syndrome treated with an antispasmodic drug
52. An assessment of dicyclomine hydrochloride ("Merbentyl") in the irritable colon syndrome
53. The GI drug column
54. 3 receptor antagonists
55. 3 receptor antagonist on experimental models of bowel dysfunction in vivo
56. Opioid action on the intestine: The importance of the intestinal mucosa
57. Pharmacology of antidiarrheal drugs
58. Role of loperamide and placebo in management of irritable bowel syndrome
59. Loperamide treatment of the irritable bowel syndrome
60. Pharmacology and clinical experience with fedotozine
61. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
62. New developments in the treatment of irritable bowel syndrome
63. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
64. Enteric neuropathobiology
65. The enteric nervous system
66. 2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors
67. The effects of granisetron, ICS 205-930, and ondansetron in the visceral pain reflex induced by duodenal distension
68. 3 antagonism (ondansetron)
69. 3 receptor antagonist, in patients with irritable bowel syndrome
70. Alosetron retards small bowel and overall transit in diarrhea predominant IBS (IBS-D)
71. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
72. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea predominant irritable bowel syndrome
73. Receptor type for cholecystokinin on isolated intestinal muscle cells of the guinea pig
74. Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture
75. Two brain cholecystokinin receptors: Implications for behavioral actions
76. Cholecystokinin in the central nervous system
77. Distribution of immunoreactive cholecystokinin in the human hippocampus
78. Cholecystokinin cells
79. Biology of gut cholecystokinin and gastrin receptors
80. Therapeutic and chemical developments of cholecystokinin receptor ligands
81. Role of cholecystokinin in regulation of gastrointestinal motor functions
82. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea
83. Modulation of gastric sensory and motor functions by nitrergic and α2-adrenergic agents in humans
84. A randomized double-blind placebo controlled trial of lidamidine HCL in irritable bowel syndrome
85. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: Analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents
86. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats
87. Intracolonic zymosan produces visceral hyperalgesia in the rat that is mediated by spinal NMDA and non-NMDA receptors
88. Role of corticotropin-releasing factor-1 (CRF1)-receptor mediated mechanisms in neural pathways modulating colonic hypersensitivity
89. Z-338 facilitates acetylcholine release from enteric neurons due to blockage of muscarinic autoreceptors in guinea pig stomach
90. 4 receptor antagonism in irritable bowel syndrome: Effect of SB-207266-A on rectal sensitivity and small bowel transit
91. Influence of buspirone-induced fundus relaxation on the perception of gastric distention in man
92. Influence of sumatriptan-induced colonic relaxation on the perception of colonic distension in man
93. Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs
94. 3 receptor
95. Comparison of the effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro
96. 17454 JL a potent optically pure prokinetic benzamide
97. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy volunteers
98. 5-Hydroxytryptamine-induced secretion by rat je-junum in-vitro involves several 5-hydroxytryptamine receptor subtypes